Navigation Links
FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
Date:3/19/2008

BOSTON, March 19 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced commencement of Phase I clinical trials for BFPET, following institutional review board (IRB) approval of the proposed studies. The Phase I trial is a single center, open label study, designed to evaluate safety, distribution and dosimetry of BFPET as a PET tracer for myocardial perfusion imaging in healthy subjects. The study will be led by Dr. Alan Fischman, Professor of Radiology at Harvard Medical School and former Director of the Nuclear Medicine Division at Massachusetts General Hospital. BFPET is FluoroPharma's second cardiovascular PET agent to enter clinical trials.

BFPET is a PET blood flow imaging agent, for use in classic "rest-stress" cardiac testing. More than 9 million Americans each year undergo myocardial perfusion imaging, the standard test to assess coronary artery disease (CAD). BFPET, as a PET imaging tracer, may have a significant advantage due to its potential to improve the sensitivity and specificity of CAD diagnosis and to provide information on myocardial mitochondrial damage. "This agent, if successful, should improve CAD diagnosis and follow-up of therapy and intervention, and broaden the utility of PET as an imaging modality," said Dr. David Elmaleh, FluoroPharma's Chairman and Scientific Founder. "BFPET has performed well in animals with a target-to-blood ratio of 70:1, and we look forward to evaluating the agent in human studies."

"We are delighted to have our second product enter clinical trials," said Dr. Ljiljana Kundakovic, FluoroPharma's President. "BFPET's progress follows on the tail of CardioPET, an agent for the detection of metabolic integrity of the heart, which recently completed a Phase I safety evaluation in normal healthy volunteers and cardiac patients. FluoroPharma has the potential to significantly impact diagnos
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
2. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
3. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
4. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
7. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
8. Synbiotics Corporation Announces Human Submission for FluDetect(R)
9. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC ...  filed a Preliminary Proxy Statement, Schedule 14A, with the U.S. ... an update for shareholders detailing why a "YES" vote to ... Dear Shareholders, As we reflect upon the 2014 ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... April 14 Today the human growth hormone ... claims benefits for enhancing athletic performance, anti-aging and ... says NAIRO, trade association of independent review organizations ... plans asking about the medical necessity of growth ...
... Arthritis Foundation, fellow co-worker , ... Nashville, TN (PRWEB) ... initiative, Camels with a Cause (CWAC) , have announced its ... fund research toward new medications to fight debilitating diseases. , , ...
... accelerated tissue healing is showing its worth in soft-tissue repair, says one ... ... first used by dental surgeons about 15 years ago to enhance wound ... (PRP) therapy is today being applied in Singapore as an alternative ...
... a Microsoft licensed solution to allow BlackBerry® devices to securely ... solution is ideal for organisations or businesses that require ActiveSync ... Server, Kerio MailServer, Zimbra Collaboration Suite or the CommuniGate Pro ... ...
... evoke compassion take longer to develop, study finds, , , ... and atwitter world might be short-circuiting your ability to ... people away from other ways of engaging with humanity ... a book. , And that ability is part ...
... (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ) WHAT: ... be the first hospital system in Wisconsin to provide ... on the Internet. Through the social networking site ... of activities and photos of the procedure. Twitter ...
Cached Medicine News:Health News:IROs Help Determine Medical Necessity of Growth Hormone Therapy 2Health News:Camels with a Cause Helps Ease the Pain of Arthritis 2Health News:Camels with a Cause Helps Ease the Pain of Arthritis 3Health News:Camels with a Cause Helps Ease the Pain of Arthritis 4Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 2Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 3Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 4Health News:NotifySync™ Provides BlackBerry a Direct Connection to Any Email Platform Supporting Microsoft ActiveSync 2Health News:E-Communication Might Be Outpacing Emotion 2Health News:Aurora St. Luke's Medical Center to Broadcast First Live Surgery Via Twitter in Wisconsin 2
Designed for peeling delicate epiretinal membrane in cases of premacular fibroplasia. Positive action closure. Barrel design with straight 20 gauge 40 gauge long shaft. 1 x 1.5 mm lightly serrated ja...
Ergotec Vetriretinal Instrument System. Ultra-fine 3.35 mm jaws. Angled 55 degrees. 20 gauge shaft. 30 mm in length. Blackened tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. 2 mm pointed tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Angled shafts with 9 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Right....
Medicine Products: